For the quarter ended December 2025, Globus Medical (GMED) reported revenue of $826.42 million, up 25.7% over the same period last year. EPS came in at $1.28, compared to $0.84 in the year-ago quarter.
The reported revenue represents a surprise of +4.9% over the Zacks Consensus Estimate of $787.85 million. With the consensus EPS estimate being $1.06, the EPS surprise was +20.76%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Globus Medical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenues- International: $161.1 million versus $147.72 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +19% change.
- Geographic Revenues- United States: $665.32 million versus the two-analyst average estimate of $621.92 million. The reported number represents a year-over-year change of +27.5%.
- Net Sales by Product Category- Enabling Technologies: $55.62 million compared to the $33.7 million average estimate based on two analysts. The reported number represents a change of +18.5% year over year.
- Net Sales by Product Category- Musculoskeletal Solutions: $770.8 million compared to the $735.95 million average estimate based on two analysts. The reported number represents a change of +26.3% year over year.
View all Key Company Metrics for Globus Medical here>>>
Shares of Globus Medical have returned +0.5% over the past month versus the Zacks S&P 500 composite's -1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Globus Medical, Inc. (GMED): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
